Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

This study is testing a combination of three drugs — isatuximab, lenalidomide, and dexamethasone (Isa-Rd) — as a gentler treatment option for frail or very elderly patients with newly diagnosed multiple myeloma, a cancer of plasma cells in the bone marrow. Standard intensive treatments may be too harsh for this group of patients. **You may be eligible if...** - You have been newly diagnosed with multiple myeloma - You are considered frail, elderly, or not a good candidate for intensive standard treatment due to health conditions or low performance - You have measurable disease confirmed by bone marrow or blood tests - You have not had more than one cycle (28 days) of prior myeloma treatment - Your blood counts and organ function meet minimum requirements **You may NOT be eligible if...** - Your doctor believes you are too frail for any systemic treatment at all - You have active infection requiring antibiotics (within the past 14 days) - You have had a heart attack or severe heart problems within the past 3 months - You have AL amyloidosis (a related but different condition) with significant organ damage - You have HIV or active hepatitis A, B, or C - You are known to be allergic to any of the study drugs Talk to your doctor to see if this trial is right for you.